Grein DX

We are honored to welcome Ole J. Dahlberg as a member of the GreinDX board. Dahlberg holds a Master's degree in General Genetics and Marine Biology from the University of Oslo (UiO). Dahlberg has more than 20 years of experience in international Life Science management.

He started his career as a scientist at Dynal ASA in 1997. Later he became a Senior Scientist at Cytomics AS, a company he co-founded in 1998. In 2000 he co-founded GenoVision, later acquired by QIAGEN in 2002, where he continued as a Managing Director and Associate Director. In 2007 he co-founded Mole Genetics AS, known for their award winning GeneMole® platform, an automated DNA extraction system. Next, in 2009, he joined Life Technologies (later acquired by Thermo Fisher Scientific) as their Segment Director. Dahlberg moved on to becoming the Managing Director for Thermo Fisher Scientific in Norway, a position he held from 2012 to 2017. Dahlberg recently returned to Norway after several years as Vice President and General Manager at Thermo Fisher Scientific in Carlsbad, California.

Ole Dahlberg is an accomplished and highly regarded international leader, with extensive board experience. He is currently on the Board of Directors for Oslo Cancer Cluster (since 2016) and Life Technologies (since 2014).

“I am very pleased that Ole J. Dahlberg will join the GreinDX team as Board member. Ole has a very interesting background and experience that will be valuable for GreinDX. He has a relevant scientific background combined with start-up experience as well as top positions at Thermo Fisher Scientific Inc, one of the world`s largest industry players within scientific instruments. Ole`s experience, perspectives and network will definitively bring enormous value to GreinDX, and I am really looking forward to working with him.”- Ove Solesvik, CEO, GreinDX

As we enter the new year we are honored to welcome Professor Bjørn Tore Gjertsen, MD, Ph.D. to our team as Scientific Advisor. Prof. Gjertsen has since 2007 been Professor of Hematology at the Department of Clinical Science at the University of Bergen (UiB) and as Research Chief and Consultant Hematologist at Helse Bergen Health Trust, developing early phase clinical trials at Haukeland University Hospital.

Prof. Gjertsen obtained his MD at the Medical Faculty at the University of Bergen in 1992 and his Ph.D. at the Medical Faculty, Department of Autonomy at the University of Bergen in 1995.

In 2016, Prof. Gjertsen was appointed co-director for Centre for Cancer Biomarkers (CCBIO), the Norwegian Centre of Excellence at the Faculty of Medicine, University of Bergen. His major research interest is the development of targeted therapy and accompanying diagnostics in the aggressive blood cancer, acute myeloid leukemia (AML). Prof. Gjertsen also established and managed the University of Bergen’s Flow Cytometry Core Facility during 2011-2017. He holds several international patents and is co-founder of two companies focusing on pre-clinical and clinical development of next generation cancer therapy, KinN Therapeutics AS and Alden Cancer Therapy AS. He is the author and co-author of numerous publications in his field.

On September 2, 2021, the Norwegian Cancer Society awarded Prof. Gjertsen, King Olav V's Prize for Cancer Research, a prestigious award honored to those who have distinguished themselves through scientific contributions to Norwegian cancer research. With over 20 years of treating patients and pioneering his field of research, he is a driven force at the institutional level aiming to strengthen the capacity to perform early clinical trials and testing novel technologies.

Photo: CCBIO/Ingvild Festervoll Melien

GreinDX har hentet in over 5 millioner i forhåndstegninger før lansering i dag klokken 12.00. Nå er muligheten åpen for alle https://folkeinvest.no/kampanje/greindx-as
Dersom du har behov for ytterligere informasjon eller ønsker å booke et møte, ønsker vi å høre fra deg.

GREINDX AS Rask og nøyaktig identifisering og analyse av kreftceller fra blodprøve muliggjør tidlig diagnose og valg av persontilpasset behandling innen timer.